- Home >
- Clinicals Trials >
- BRIDGE (D9106C00002)
Retour à la liste des essais cliniquesLung cancer
BRIDGE (D9106C00002)
A multicentre, Phase II, single-arm, interventional study of;neoadjuvant durvalumab and platinum-based chemotherapy;(CT), followed by either surgery and adjuvant durvalumab or;chemoradiotherapy (CRT) and consolidation durvalumab, in;participants with resectable or borderline resectable stage;IIB-IIIB Non-small Cell Lung Cancer (NSCLC)
- Ouvert à Paris depuis le : 14/06/2024
- Public cible : Adult
- Phase : Phase II
Description de l'essai
To assess the efficacy of neoadjuvant durvalumab +;CT in terms of resection rate in participants with;resectable and borderline resectable stage IIB-IIIB;NSCLC.;Resection rate defined as the proportion of all;participants who underwent definitive surgery.;The analysis will be performed in all participants who;received at least one dose of study intervention (FAS).
Url of the trialInvestigateur principal
